IL2 and melanoma: The short-lived therapeutic response, tumor resistance, and adverse effects of traditional drugs used in melanoma therapy, including dacarbazine, temozolomide and interleukin-2, along with recently approved targeted therapeutic agents, such as vemurafenib and ipilimumab, have limited their use due to low responsive rates and/or high toxicities [3]–[5].